[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"grass-pollen-allergy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:grass-pollen-allergy":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":35,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100597211","creating-a-risk-assessment-tool-for-thunderstorm-asthma-the-carista-study-100597211",false,"NCT07055542","Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study","Creating A RIsk Assessment Biomarker Tool to Prevent Seasonal and Thunderstorm Asthma: The CARISTA Study","CARISTA","Inclusion Criteria:\n\nConsenting adults aged 18 to 70 years with seasonal allergic rhinitis\n\nwilling to undertake:\n\n* Lung function testing\n* Blood sample collection for risk factor identification, -Prospectively logging their symptoms and medications through the springtime season using the CARISTA symptom monitoring platform . -\n\nExclusion Criteria:\n\n* Individuals unable to provide informed consent\n* Individuals who do not suffer from symptoms of seasonal allergic rhinitis\n* Individuals who do not consent to lung function testing and blood sample collection - Individuals with unstable asthma (FEV1 by spirometry less than 70% predicted), a recent exacerbation or change of asthma preventive medication use (within one month) would be excluded, although re-screening would be permitted after one month, time permitting.\n* Individuals with severe asthma requiring the use of continuous oral corticosteroids or biological medication for severe asthma.\n* The presence of any medical illness, such as cardiac disease, pre-existing illness or immunomodulatory therapy that, in the opinion of the Investigators, would compromise participant safety or the derivation of biomarkers during the study.",true,"ALL","18 Years","70 Years",{"count":22,"type":23},530,"ESTIMATED","INTERVENTIONAL",[26],"NA","Thunderstorm asthma is a recurring public health emergency in South-Eastern Australia which occurs in springtime. The major identified risk factors for thunderstorm asthma is hay fever and allergy to ryegrass pollen. The goal of the CARISTA study is to identify the risk of springtime allergic and thunderstorm asthma in allergic adults living in South-Eastern Australia. To do this the investigators will recruit 530 people who have hay fever and test them for allergy to ryegrass pollen and undertake simple lung function testing. The investigators will ask study participants to complete a customised symptom tracker over the springtime pollen season for 2 consecutive years. The outcome the investigators are looking for is an asthma exacerbation or worsening asthma symptoms. This study will enable the investigators to identify indicators (biomarkers) of severe and moderate asthma exacerbations in order to identify those at risk of thunderstorm and seasonal asthma so protective treatments and strategies can be advised.",[29,30,31,32,33,34],"Allergic Asthma","Thunderstorm Asthma","Seasonal Allergic Rhinitis","Grass Pollen Allergy","Asthma Exacerbation Due to Thunderstorm","Asthma Acute",[36,37,38,39,40,41,42,43,44,45],"asthma","allergy","grass pollen allergy","ryegrass pollen","prospective symptom monitoring","seasonal allergic rhinitis","hay fever","seasonal allergic rhinoconjunctivitis","serum specific IgE","spirometry","RECRUITING","2026-04-29",{"date":49,"type":50},"2026-05-06","ACTUAL",{"date":52,"type":50},"2025-08-27",{"date":54,"type":23},"2030-12-31",{"name":56,"class":57},"University of Melbourne","OTHER",6,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100624696","grass-grass-mata-mpl-real-world-assessment-study-100624696","NCT07412990","GRASS (Grass MATA MPL Real-world Assessment Study)","Eine Prospektive, Offene, Multizentrische, Nicht-interventionelle Studie Zur Erhebung Von Daten Zur Anwendung Von Grass MATA MPL 27 600 SU Und Compliance in Der täglichen Klinischen Praxis Bei Erwachsenen Gräserpollen- Allergikern","GRASS","At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who\n\n* are male and female patients\n* are 18 years of age or older\n* treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and\u002For rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen.\n* Patients will only be enrolled in the study after the treatment decision has been made\n\nExclusion Criteria:\n\nAt the physician's discretion, the study should not be offered to the following patients:\n\n* Patients who are not sufficiently proficient in or do not adequately understand the German language, as this would prevent adequate comprehension of study-relevant documents.\n* In addition, patients should not be included if any of the contraindications listed in the current Summary of Product Characteristics (SmPC) are present.",{"count":68,"type":23},1000,"OBSERVATIONAL","Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.",[32],[73],"Allergy, Grass-pollen, AIT, SCIT","2026-03-19",{"date":76,"type":50},"2026-03-20",{"date":78,"type":50},"2026-03-11",{"date":80,"type":23},"2028-10-02",{"name":82,"class":83},"Allergy Therapeutics","INDUSTRY",1]